Loading organizations...
Nimble Science offers the SIMBA GI Platform, a technology for precise small intestine sampling. The SIMBA Capsule collects intestinal fluid biopsies, yielding multi-omic datasets from the entire gastrointestinal tract, with emphasis on the small intestine. This innovation facilitates at-home intestinal fluid biopsies, contributing to a proprietary database of small intestinal data.
The company originated from a need for improved, non-invasive small intestine analysis. Specific founding details are not publicly available, but the team developed their novel sampling system from the insight that existing methods lacked precision for comprehensive gut health assessment. This led to their unique approach to targeted intestinal fluid collection.
The platform supports biopharma and nutrition researchers, alongside clinical investigations into GI disorders. Nimble Science envisions advancing precision sampling and healthcare innovation. Their mission is to enable accurate and accessible tools, enhancing the understanding and improvement of human gut health through intestinal insights.
Nimble Science has raised $2.0M across 1 funding round.
Nimble Science has raised $2.0M in total across 1 funding round.
Nimble Science has raised $2.0M in total across 1 funding round.
Nimble Science's investors include Family Office, Framework Venture Partners, Intuit Ventures, Alumni Ventures, Bascom Ventures.
Nimble Science has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in February 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2023 | $2M Seed | — | Family Office, Framework Venture Partners, Intuit Ventures, Alumni Ventures, Bascom Ventures | Announced |
Nimble Science is a biotechnology company developing the SIMBA capsule, an ingestible device for passive sampling of small intestine luminal fluid to generate multi-omic microbiome datasets.[1][2][4] It serves pharmaceutical, diagnostic, nutritional, and medical research industries by enabling at-home collection of previously inaccessible gut data, solving the problem of limited insights into small intestine microbiomes critical for disease detection, personalized medicine, and product innovation.[1][3][5] The platform offers an "as-a-service" model with data analytics, earning recognition as NutraIngredients-USA's 2024 Startup of the Year for advancing personalized microbiome interventions.[1][3]
Growth momentum includes clinical validation against gold-standard methods like naso-intestinal catheters, yielding 20 times higher bacterial DNA than endoscopy, two patent filings in bacteriology and digestive systems, and partnerships for North American trials since 2021.[1][4][5] With under $5M in funding across one round, Nimble operates from Calgary, Canada, focusing on scalable GI analytics.[4][7]
Nimble Science was founded in 2018 by Dr. Gang (Joseph) Wang, PhD (co-founder and CTO), and Dr. Sabina Bruehlmann, PhD (CEO), both University of Calgary doctorate recipients with expertise in gut microbiome research.[1][4] The idea emerged from Hippocrates' insight that "all disease begins in the gut," driving development of the SIMBA (Small Intestine MicroBiome Aspiration) capsule for non-invasive small intestine sampling to revolutionize disease detection and treatment.[4]
Early traction came via collaborations with University of Calgary's Division of Gastroenterology and Lallemand Health Solutions, launching clinical studies in 2021.[4] Support from UCeed, Innovate Calgary, Hunter Hub, and Creative Destruction Lab accelerated progress to clinical-stage trials and industry partnerships.[4] Pivotal moments include a 2024 NutraIngredients award and platform launch providing contextual data analysis.[1][3]
Nimble rides the gut microbiome revolution in precision medicine, where small intestine data—housing bioactive microbes influencing 70-80% of immunity and nutrient absorption—has been inaccessible without invasive procedures.[1][4][5] Timing aligns with surging demand for personalized GI interventions amid rising digestive disorders, microbiome therapeutics, and nutraceuticals, amplified by post-2020 focus on at-home diagnostics.[3][5]
Market forces favoring Nimble include scalability of non-invasive sampling over endoscopy, enabling faster pharma R&D and probiotic development, plus AI-driven omics analysis.[2][6] It influences the ecosystem by partnering with leaders (e.g., Lallemand), powering consortia therapeutics like MRM Health's CORAL, and shifting paradigms from plate-to-bedside GI care.[2][4]
Nimble Science is poised to dominate small intestine sampling with its validated SIMBA platform, expanding "as-a-service" to more pharma and nutraceutical trials while building its omics database.[1][5] Trends like AI-multiomics integration, microbiome drugs for Parkinson's and beyond, and at-home precision health will propel growth, potentially through Series A funding or acquisitions by GI giants.[2][7]
Its influence may evolve from R&D enabler to direct diagnostic tool, tying back to the core promise: unlocking gut data to prevent disease at its source.[4]
